CP and COVID-19: A study conducted by Salazar et al. [92] showed significant reduction in mortality (p = 0.047) was observed when CP from a donor patient was used as a source of antibodies within 28 days of collection, and several human trials are being conducted to better understand and evaluate CP as a method of treatment for COVID-19 [92].